The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
ASH 2016 | Results of trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in CLL
Stephan Stilgenbauer, MD, PhD of Ulm University, Ulm, Germany discusses the Phase Ib trial of venetoclax with bendamustine/rituximab or bendamustine/obinutuzumab in patients with relapsed/refractory or previously untreated chronic lymphocytic leukemia (CLL) (NCT01671904). Prof. Stilgenbauer explains that venetoclax is a first-in-class BCL-2 inhibitor. The key results are that this combination is well-tolerated, efficacy is very good, with very deep remissions being achieved and patients becoming minimal residual disease (MRD) negative, and further, some patients can stop treatment.
Recorded at the 2016 American Society of Hematology (ASH) Annual Meeting, held in San Diego, CA.
